학술논문
A Potential Biomarker of Dynamic Change in Peripheral CD45RA − CD27 + CD127 + Central Memory T Cells for Anti-PD-1 Therapy in Patients with Esophageal Squamous Cell Carcinoma.
Document Type
Article
Author
Source
Subject
*BIOMARKERS
*FLOW cytometry
*IMMUNE checkpoint inhibitors
*CANCER chemotherapy
*TREATMENT effectiveness
*CHEMORADIOTHERAPY
*ENZYME-linked immunosorbent assay
*T cells
*IMMUNOLOGIC memory
*DATA analysis software
*SQUAMOUS cell carcinoma
*ESOPHAGEAL cancer
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2072-6694
Abstract
Simple Summary: In order to develop a biomarker predicting the efficacy of chemotherapy (CT), chemoradiotherapy (CRT), and nivolumab therapy (NT) for patients with esophageal squamous cell carcinoma (ESCC), we evaluated the subpopulation of T cells in ESCC patients treated with each therapy. The frequencies of PD-1+ or TIM-3+CD4+ T cells were significantly higher in patients with cStage IV. PD-1+CD4+ and TIM-3+CD8+ T-cell populations were significantly higher in patients treated with CRT but were not associated with treatment response. The frequencies of both CD4+ and CD8+ central memory T cells (TCM) were significantly decreased during NT in the progressive disease group. Taken together, the alteration in frequency of TCM during NT may be a biomarker to predict its therapeutic response in ESCC patients. In order to develop a biomarker predicting the efficacy of treatments for patients with esophageal squamous cell carcinoma (ESCC), we evaluated the subpopulation of T cells in ESCC patients treated with chemotherapy (CT), chemoradiotherapy (CRT), and nivolumab therapy (NT). Fifty-five ESCC patients were enrolled in this study, and peripheral blood samples were collected before and after CT or CRT and during NT. Frequencies of memory, differentiated, and exhausted T cells were evaluated using flow cytometry among cStages, treatment strategies, pathological responses of CT/CRT, and during NT. The frequencies of PD-1+ or TIM-3+CD4+ T cells were significantly higher in patients with cStage IV. PD-1+CD4+ and TIM-3+CD8+ T-cell populations were significantly higher in patients treated with CRT but were not associated with treatment response. The frequencies of both CD4+ and CD8+ CD45RA−CD27+CD127+ central memory T cells (TCM) were significantly decreased during the course of NT in the progressive disease group. Taken together, the alteration in frequency of CD45RA−CD27+CD127+ TCM during NT may be a biomarker to predict its therapeutic response in ESCC patients. [ABSTRACT FROM AUTHOR]